A dose-dependent controlled trial of human lymphoblastoid interferon α for genotype 1b chronic hepatitis C associated with high HCV-RNA levels

Hepatology Research

Volumn 7, Issue 2, 1997, Pages 105-112

  Komatsu, Masafumi ^a   Ishii, Tohru ^a   Ono, Tsuyoshi ^a   Kuramitsu, Tomoyuki ^a   Hoshino, Takao ^a   Masamune, Osamu ^a   Yoshida, Tsukasa ^b   Yagisawa, Hitoshi ^c   Yamada, Nobuo ^d  

^a AKITA UNIVERSITY   (Japan)

^b AKITA CITY HOSPITAL   (Japan)

^c Japan Organization of Occupational Health and Safe   (Japan)

^d Yuri Kumiai General Hospital   (Japan)

Author keywords

Chronic hepatitis C; Hepatitis C virus genotype 1b; Interferon therapy; Randomized controlled study; Serum HCV RNA levels

Indexed keywords

ALPHA INTERFERON; LYMPHOBLAST INTERFERON; VIRUS RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS TYPING;

EID: 0030837128     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-4346(97)00026-1     Document Type: Article

References (18)

1. Hagiwara H, Hayashi N, Mita E, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alpha therapy. Gastroenterology 1993; 104: 877-883.
2. Lau JY, Davis GL, Kniffen J, Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-1504.
3. Kanai K, Kako M, Okamoto H, HCV genotypes in chronic hepatitis C and response to interferon. Lancet 1992; 339: 1543.
4. Yoshioka K, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: Relationship to genotypes of hepatitis C virus. Hepatology 1992; 16: 293-299.
5. Kanazawa Y, Hayashi N, Mita E, Li T, Hagiwara H, Kasahara A, Fusamoto H, Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 1994; 20: 1121-1130.
6. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus Ib infection. N Engl J Med 1996; 334: 77-81.
7. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435.
8. Okamoto H, Okada S, Kurai K, Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Japan J Exp Med 1994; 60; 215-222.
9. Ishiyama N, Katayama K, Ishimi N, Takahashi S, Igarashi H, Nakajima H, Multicyclic RT-PCR: A new quantitative method for hepatitis C virus and its comparison with modified CRT-PCR. Acta Hepatol Jpn 1992; 1: 506-507.
10. Okamoto H, Kurai K, Okada S, et al. Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: Comparative study of four distinct genotypes. Virology 1992; 188: 331-341.
11. Simmonds P, Alberti A, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-1324.
12. Takada A, Tsutsumi M, Okanoue T, Matsushima M, Komatsu M, Fujiyama S, Distribution of the different subtypes of hepatitis C virus in Japan and the effects of interferon: A nationwide survey. J Gastroenterol Hepatol 1996; 11: 201-207.
13. Kobayashi Y, Watanabe S, Konishi M, et al. Quantitation and typing of hepatitis C virus RNA in patients with chronic hepatits C treated with Interferon-β. Hepatology 1993; 18: 1319-1325.
14. Arase Y, Kumada H, Chayama K, et al. Interferon retreatment of nonresponder with HCV-RNA-positive chronic hepatitis. C J Gastroenterol 1994; 29: 299-304.
15. Terada M, Baba T. Ota M, et al. Interferon treatment for chronic hepatitis C: Assessment of three regimens in patients who received more than 500 MU interferon treatment and the effect of predictive factors for interferon treatment using multivariate analysis with the logistic regression model. Jpn Gastroenterol 1995; 92: 56-61.
16. Kasahara A, Hayashi N, Hiramatsu N, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: Multicenter randomized controlled trial. Hepatology 1995; 21: 291-297.
17. Reichard O, Foberg U, Fryden A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α 2b for 60 weeks. Hepatology 1994; 19: 280-285.
18. Brillanti S, Garson J, Foli M, et al. A pilot study of combination therapy with ribavirin plus interferon alpha for interferon α-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812-817.